<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091099</url>
  </required_header>
  <id_info>
    <org_study_id>202108044MINA</org_study_id>
    <nct_id>NCT05091099</nct_id>
  </id_info>
  <brief_title>The Optimal Sequential Therapy After Long Term Denosumab Treatment</brief_title>
  <official_title>The Optimal Sequential Therapy After Long Term Denosumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to investigate whether Alendronate and Zoledronate can prevent bone&#xD;
      mineral density loss after long-term treatment with Denosumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study intends to use a randomized trial to test whether Alendronate and Zoledronate can&#xD;
      avoid the risk of rapid bone loss after the withdrawal of Denosumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One arm accept on time zoledronic acid after long-tearm denosumab. Another arm accept alendronate for 4 months and then zoledronic acid after long-tearm denosumab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density of lumbar spine</measure>
    <time_frame>one year</time_frame>
    <description>Bone mineral density of lumbar spine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density of femoral neck</measure>
    <time_frame>one year</time_frame>
    <description>Bone mineral density of femoral neck</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density of total hip</measure>
    <time_frame>one year</time_frame>
    <description>Bone mineral density of total hip</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>On time Zoledronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronate would be given (one dose for one year) after the completiong of denosumab on time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate and Zoledronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).</description>
    <arm_group_label>Alendronate and Zoledronate</arm_group_label>
    <arm_group_label>On time Zoledronate</arm_group_label>
    <other_name>Zoledronic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal women or men over 50 years old&#xD;
&#xD;
          2. Denosumab treatment for at least two years and less than three years (up to five&#xD;
             doses).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Estimated glomerular filtration rate &lt;35 ml/min.&#xD;
&#xD;
          2. Malignancy&#xD;
&#xD;
          3. Continuous steroid treatment, hormone therapy or other medical treatment affecting&#xD;
             bone metabolism&#xD;
&#xD;
          4. Secondary osteoporosis&#xD;
&#xD;
          5. Metabolic bone diseases&#xD;
&#xD;
          6. Contraindications to ZOL&#xD;
&#xD;
          7. Patients older than 80 years old&#xD;
&#xD;
          8. Hypocalcemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shau-Huai Fu, Doctor</last_name>
    <phone>+886972655734</phone>
    <email>b90401045@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen-Yu Wang, Doctor</last_name>
    <phone>+886952489782</phone>
    <email>valinawang0220@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yunlin branch</name>
      <address>
        <city>Douliu</city>
        <state>Yunlin County</state>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shau-Huai Fu, Doctor</last_name>
      <phone>+886972655734</phone>
      <email>b90401045@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chen-Yu Wang, Doctor</last_name>
      <phone>+886952489782</phone>
      <email>valinawang0220@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>denosumab</keyword>
  <keyword>alendronate</keyword>
  <keyword>zoledronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>after application</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

